Close Menu

product launch

DNAstack offers cloud-based access to bioinformatics solutions and mechanisms for sharing genomic data that leverage open APIs and resources. 

The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.

The app lets physicians use their mobile phones to access clinical trial matching capabilities from the broader GenoSpace portfolio.

Frameshift plans to commercialize two applications: one for data quality control and a second for identifying mutations in rare and Mendelian disorders.

Living DNA can break down the origins of a customer’s ancestry into 21 distinct regions within Britain alone, as well as across 80 different worldwide populations.

The platform features a more comprehensive list of pipelines, simplifies data movement and flow, and reduces analysis times.

The launch follows a beta that kicked off earlier this year to put the software through its paces with data curators and other scientists.

Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.

Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests. 

The company emerged from stealth mode this month and traces roots to both rocket maker SpaceX and the shuttered sequencing company Halcyon Molecular. 

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.